Table 4.
The effect on hip fracture (number/1000 patient years) of an anabolic agent (AA) given for the first 18 months followed by an antiresorptive (AR) for a total of 10 years. The clinical scenario is a postmenopausal woman from the UK with a recent major osteoporotic fracture. The efficacy (RRR) of the anabolic agent is modelled at 70% and that of the antiresorptive at 40%. The time course of a subsequent hip fracture is non-linear as given in [58]. The two right-hand columns show the effects of an antiresorptive followed by an anabolic agent for the last 18 months of a 10-year treatment
| Untreated | AA/AR RRR 70/40%a |
Fractures savedb | AR/AN RRR 40/70% |
Fractures savedb | |
|---|---|---|---|---|---|
| Age | N/1000 | N/1000 | N/1000 | N/1000 | N/1000 |
| 50 | 8.1 | 2.4 | 5.7 | 4.7 | 3.4 |
| 55 | 12.8 | 3.8 | 9.0 | 7.5 | 5.3 |
| 60 | 20.4 | 6.1 | 14.3 | 11.9 | 8.5 |
| 65 | 31.3 | 9.4 | 21.9 | 18.3 | 13.0 |
| 70 | 48.3 | 14.5 | 33.8 | 28.3 | 20.0 |
| 75 | 73.6 | 22.1 | 51.5 | 43.1 | 30.5 |
| 80 | 104.7 | 31.4 | 73.3 | 61.2 | 43.5 |
| 85 | 160.4 | 48.1 | 112.3 | 93.8 | 66. 6 |
| 90 | 180.9 | 54.3 | 126.6 | 105.8 | 75.1 |
aIt is assumed that the effect of the anabolic agent is maintained with the subsequent antiresorptive agent
bFirst fractures